In collaboration with PA Media Group

• Health & Medicine
• Science & Technology

Genetic changes in tumours may predict who will respond to immunotherapy

Genetic changes in tumours could be used to predict who will benefit from immunotherapy, and who should receive other treatments.  Genetic changes in tumours could be used to predict who will benefit from immunotherapy, and who should receive other treatments. 

27 January 2021

• Health & Medicine

NHS patients among first to access new CAR T cell therapy for lymphoma

Lymphoma patients in England are among the first in the world to be offered new CAR T cell therapy. Lymphoma patients in England are among the first in the world to be offered new CAR T cell therapy.

20 January 2021

• Health & Medicine

NICE approves new maintenance treatment for ovarian cancer

A new targeted treatment has been recommended by the National Institute of Health and Care Excellence for some adults with ovarian cancer. A new targeted treatment has been recommended by the National Institute of Health and Care Excellence for some adults with ovarian cancer.

19 January 2021

• Health & Medicine

Scottish Medicines Consortium says yes to chemotherapy-free leukaemia treatment

The Scottish Medicines Consortium (SMC) has approved a new chemotherapy-free treatment option for some adults with untreated chronic lymphocytic leukaemia. The Scottish Medicines Consortium (SMC) has approved a new chemotherapy-free treatment option for some adults with untreated chronic lymphocytic leukaemia.

8 December 2020

• Health & Medicine

Rare bowel cancer treatment combo gets initial no for NHS use in England  

A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence. A drug combination for people with a rare type of bowel cancer has received an initial rejection from the National Institute for Health and Care Excellence.

4 September 2020

• Health & Medicine

Targeted treatment for leukaemia approved on NHS in England 

The targeted drug gilteritinib is now recommended for some adults with acute myeloid leukaemia (AML) on the NHS in England.   The targeted drug gilteritinib is now recommended for some adults with acute myeloid leukaemia (AML) on the NHS in England.  

16 July 2020

• Health & Medicine

New treatment for rare blood cancer approved for NHS use in England

The National Institute for Health and Care Excellence (NICE) has approved the drug brentuximab vedotin on the NHS in England. The National Institute for Health and Care Excellence (NICE) has approved the drug brentuximab vedotin on the NHS in England.

10 July 2020

• Health & Medicine

Prostate cancer hormone therapy not recommended for NHS in England

A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer. A hormone therapy has been rejected for some adults with newly-diagnosed, advanced prostate cancer.

26 June 2020

• Health & Medicine

Targeted drug improves survival for children with non-Hodgkin lymphoma

New clinical trial results show that adding rituximab to standard chemotherapy could improve survival for some children with non-Hodgkin lymphoma. New clinical trial results show that adding rituximab to standard chemotherapy could improve survival for some children with non-Hodgkin lymphoma.

25 June 2020

• For Supporters

Cancer Research UK stores to reopen from 29 June  

Cancer Research UK’s charity shops will start to reopen to the public from 29 June in England, and 6 July in Northern Ireland. Cancer Research UK’s charity shops will start to reopen to the public from 29 June in England, and 6 July in Northern Ireland.

17 June 2020

• Health & Medicine

Immunotherapy treatment recommended for advanced small cell lung cancer 

A new immunotherapy treatment has been recommended by the National Institute for Health and Care Excellence (NICE) for some adults with small cell lung cancer. A new immunotherapy treatment has been recommended by the National Institute for Health and Care Excellence (NICE) for some adults with small cell lung cancer.

5 June 2020

• Health & Medicine

Immunotherapy for triple negative breast cancer approved for NHS in England 

Atezolizumab used in combination with nab-paclitaxel is the first immunotherapy available for triple negative breast cancer. Atezolizumab used in combination with nab-paclitaxel is the first immunotherapy available for triple negative breast cancer.

26 May 2020